首页> 外文期刊>International journal of oncology >Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma
【24h】

Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma

机译:叶酸受体靶向纳米粒子对恶性胸膜间皮瘤光动力治疗的临床前研究

获取原文
       

摘要

Photodynamic therapy (PDT) following lung- sparing extended pleurectomy for malignant pleural mesothelioma (MPM) has been investigated as a potential means to kill residual microscopic cells. High expression levels of folate receptor 1 (FOLR1) have been reported in MPM; therefore, targeting FOLR1 has been considered a novel potential strategy. The present study developed FOLR1-targeting porphyrin-lipid nanoparticles (folate-porphysomes, FP) for the treatment of PDT. Furthermore, inhibition of activated epidermal growth factor (EGFR)-associated survival pathways enhance PDT efficacy. In the present study, these approaches were combined; FP-based PDT was used together with an EGFR-tyrosine kinase inhibitor (EGFR-TKI). The frequency of FOLR1 and EGFR expression in MPM was analyzed using tissue microarrays. Confocal microscopy and a cell viability assay were performed to confirm the specificity of FOLR1-targeting cellular uptake and photocytotoxicity in vitro . In vivo fluorescence activation and therapeutic efficacy were subsequently examined. The effects of EGFR-TKI were also assessed in vitro . The in vivo combined antitumor effect of EGFR-TKI and FP-PDT was then evaluated. The results revealed that FOLR1 and EGFR were expressed in 79 and 89% of MPM samples, respectively. In addition, intracellular uptake of FP corresponded well with FOLR1 expression. When MPM cells were incubated with FP and then irradiated at 671 nm, there was significant in vitro cell death, which was inhibited in the presence of free folic acid, thus suggesting the specificity of FPs. FOLR1 targeting resulted in disassembly of the porphysomes and subsequent fluorescence activation in intrathoracic disseminated MPM tumors, as demonstrated by ex vivo tissue imaging. FP-PDT resulted in significant cellular damage and apoptosis in vivo . Furthermore, the combination of pretreatment with EGFR-TKI and FP-PDT induced a marked improvement of treatment responses. In conclusion, FP-based PDT induced selective destruction of MPM cells based on FOLR1 targeting, and pretreatment with EGFR-TKI further enhanced the therapeutic response.
机译:肺保护性扩大胸膜切除术后恶性胸膜间皮瘤(MPM)的光动力疗法(PDT)已被研究为杀死残留微小细胞的潜在手段。 MPM中已经报道了叶酸受体1(FOLR1)的高表达水平。因此,靶向FOLR1被认为是一种新颖的潜在策略。本研究开发了靶向FOLR1的卟啉-脂质纳米颗粒(叶酸-卟啉体,FP)来治疗PDT。此外,抑制活化的表皮生长因子(EGFR)相关的生存途径可以增强PDT的功效。在本研究中,将这些方法结合在一起。基于FP的PDT与EGFR酪氨酸激酶抑制剂(EGFR-TKI)一起使用。使用组织微阵列分析了MPM中FOLR1和EGFR表达的频率。共聚焦显微镜和细胞活力测定进行了确认FOLR1靶向细胞摄取和体外光毒性的特异性。随后检查体内荧光激活和治疗功效。还评估了EGFR-TKI的作用。然后评价EGFR-TKI和FP-PDT的体内联合抗肿瘤作用。结果显示FOLR1和EGFR分别在79%和89%的MPM样品中表达。另外,FP的细胞内摄取与FOLR1表达很好地对应。当MPM细胞与FP一起孵育,然后在671 nm处照射时,存在明显的体外细胞死亡,在游离叶酸的存在下细胞死亡被抑制,因此表明FP的特异性。 FOLR1靶向导致胸腔内散布的MPM肿瘤中的卟啉体分解和随后的荧光激活,如离体组织成像所示。 FP-PDT在体内导致明显的细胞损伤和细胞凋亡。此外,EGFR-TKI和FP-PDT联合预处理可显着改善治疗反应。总之,基于FP的PDT基于FOLR1靶向诱导了MPM细胞的选择性破坏,而EGFR-TKI预处理进一步增强了治疗反应。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号